Symbiosis Pharmaceutical

Activities: Manufacturing

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From proof-of-concept to commercial reality: a turning point for microneedle drug delivery A 50% reduction in microarray patch production costs demonstrates that scalable, automated MAP manufacturing is now commercially viable — clearing a critical barrier to...
  2. The future of aseptic manufacturing: Compact and advanced solutions As the pharmaceutical industry advances into more complex modalities, from biologics to cell and gene therapies, the need for flexible, aseptically robust fill-finish solutions...
  3. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  4. Labtex Labtex is a specialist laboratory and process chemistry equipment solutions provider. A dynamic team of professionals with expertise in research and process development across...
  5. Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™ Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

Related Content

Symbiosis appoints Joanne Anderson as chief commercial officer

Strategic return strengthens commercial leadership as sterile fill-finish CDMO expands global footprint
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

Symbiosis expands sterile manufacturing capacity with fill/finish line qualification

Symbiosis has maintained a track record of successful GMP inspections with both the FDA and MHRA since it was founded
Manufacturing

Symbiosis reaches major milestone with 1,000th batch of injectable drug product

Symbiosis Pharmaceutical Services, a global contract manufacturing organisation (CMO), today announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in its mission to accelerate access to life-changing medicines worldwide
Manufacturing

Symbiosis appoints Angelika Rublack as Senior Business Development Manager

Symbiosis expands global reach with key appointment of Angelika Rublack as Senior Business Development Manager

Symbiosis honoured with prestigious King’s Award for Enterprise for International Trade

Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category, the UK’s highest official accolade for British businesses
Manufacturing

Symbiosis completes successful MHRA audit of new sterile fill/finish facility

Symbiosis completes successful MHRA audit of new sterile fill/finish facility, expanding global manufacturing capacity
Subscribe now